Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8991511 | 0.88 | GMNN (0.36) | GMNNLMNAMAPTPMP22SMN1; SMN2 | |
| SCHEMBL20438492 | 0.85 | GMNN (0.38) | GMNNLMNAMAPTPMP22SMN1; SMN2 | |
| SCHEMBL18935281 | 0.82 | GMNN (0.30) | GMNNLMNAMAPTPMP22SMN1; SMN2 | |
| SCHEMBL21237668 | 0.81 | — | — | |
| SCHEMBL19542943 | 0.74 | GMNN (0.36) | GMNNLMNAMAPTPMP22SMN1; SMN2 | |
| SCHEMBL7002845 | 0.72 | — | — | |
| SCHEMBL10100200 | 0.72 | — | — | |
| SCHEMBL7002850 | 0.72 | — | — | |
| SCHEMBL27985827 | 0.72 | GMNN (0.41) | GMNNLMNAMAPTPMP22SMN1; SMN2 | |
| SCHEMBL21286297 | 0.69 | PIK3CD (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | GMNN 1396/4885LMNA 2826/4885MAPT 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.